AU2020350524B2 - Immunotherapy compounds and methods - Google Patents

Immunotherapy compounds and methods

Info

Publication number
AU2020350524B2
AU2020350524B2 AU2020350524A AU2020350524A AU2020350524B2 AU 2020350524 B2 AU2020350524 B2 AU 2020350524B2 AU 2020350524 A AU2020350524 A AU 2020350524A AU 2020350524 A AU2020350524 A AU 2020350524A AU 2020350524 B2 AU2020350524 B2 AU 2020350524B2
Authority
AU
Australia
Prior art keywords
compound
seq
domain
cells
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020350524A
Other languages
English (en)
Other versions
AU2020350524A1 (en
Inventor
Martin FELICES
Jeffrey S. Miller
Martin Schroeder
Daniel A. Vallera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GT Biopharma Inc
University of Minnesota System
Original Assignee
University of Minnesota Twin Cities
GT Biopharma Inc
University of Minnesota System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota Twin Cities, GT Biopharma Inc, University of Minnesota System filed Critical University of Minnesota Twin Cities
Publication of AU2020350524A1 publication Critical patent/AU2020350524A1/en
Application granted granted Critical
Publication of AU2020350524B2 publication Critical patent/AU2020350524B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
AU2020350524A 2019-09-16 2020-09-15 Immunotherapy compounds and methods Active AU2020350524B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901198P 2019-09-16 2019-09-16
US62/901,198 2019-09-16
PCT/US2020/050851 WO2021055342A1 (en) 2019-09-16 2020-09-15 Immunotherapy compounds and methods

Publications (2)

Publication Number Publication Date
AU2020350524A1 AU2020350524A1 (en) 2022-04-21
AU2020350524B2 true AU2020350524B2 (en) 2026-07-09

Family

ID=74883667

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020350524A Active AU2020350524B2 (en) 2019-09-16 2020-09-15 Immunotherapy compounds and methods

Country Status (10)

Country Link
US (1) US20220324972A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031565A4 (cg-RX-API-DMAC7.html)
JP (2) JP7773152B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220087441A (cg-RX-API-DMAC7.html)
CN (1) CN115023435B (cg-RX-API-DMAC7.html)
AU (1) AU2020350524B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022004712A2 (cg-RX-API-DMAC7.html)
CA (1) CA3154158A1 (cg-RX-API-DMAC7.html)
IL (1) IL291343A (cg-RX-API-DMAC7.html)
WO (1) WO2021055342A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
CN118201961A (zh) * 2021-09-16 2024-06-14 Gt生物制药公司 Pd-l1靶向融合蛋白及其使用方法
WO2025136820A1 (en) * 2023-12-18 2025-06-26 Regents Of The University Of Minnesota Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062604A1 (en) * 2015-10-06 2017-04-13 Regents Of The University Of Minnesota Therapeutic compounds and methods
JP2018524373A (ja) * 2015-07-15 2018-08-30 ザイムワークス,インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104640561A (zh) * 2012-07-23 2015-05-20 酵活有限公司 包含轻链和重链的选择性配对的免疫球蛋白构建体
EP3066470A4 (en) * 2013-11-05 2017-05-31 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
CA2953816C (en) * 2014-06-30 2022-03-15 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018524373A (ja) * 2015-07-15 2018-08-30 ザイムワークス,インコーポレイテッド 薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
WO2017062604A1 (en) * 2015-10-06 2017-04-13 Regents Of The University Of Minnesota Therapeutic compounds and methods

Also Published As

Publication number Publication date
KR20220087441A (ko) 2022-06-24
WO2021055342A1 (en) 2021-03-25
BR112022004712A2 (pt) 2022-06-14
JP2026021424A (ja) 2026-02-10
EP4031565A4 (en) 2023-10-25
CN115023435B (zh) 2026-03-27
AU2020350524A1 (en) 2022-04-21
EP4031565A1 (en) 2022-07-27
JP7773152B2 (ja) 2025-11-19
JP2022548145A (ja) 2022-11-16
US20220324972A1 (en) 2022-10-13
IL291343A (en) 2022-05-01
CA3154158A1 (en) 2021-03-25
CN115023435A (zh) 2022-09-06